Progenity Acquires Proteomic Dx Firm Carmenta Bioscience | GenomeWeb

NEW YORK (GenomeWeb) – Progenity said today that it has acquired proteomic diagnostic company Carmenta Bioscience.

A spin-out of Stanford University, Carmenta is focused on developing a protein-based test for preeclampsia, a hypertensive disorder of pregnancy. Preeclampsia is a leading cause of preterm births and maternal fetal deaths, with between 5 and 8 percent of pregnant women developing the condition.

Under the terms of the acquisition, Carmenta CEO Matthew Cooper will join Progenity as chief scientific officer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.